$24.00
2.91% yesterday
Nasdaq, Oct 03, 10:16 pm CET
ISIN
US8902604094
Symbol
TNXP

Tonix Pharmaceuticals Holding Corp. Stock price

$24.00
-3.70 13.36% 1M
+6.51 37.22% 6M
-8.98 27.23% YTD
+11.40 90.48% 1Y
-10,974.00 99.78% 3Y
-505,640.00 100.00% 5Y
-4,102,399,976.00 100.00% 10Y
-1,279,976.00 100.00% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.72 2.91%
ISIN
US8902604094
Symbol
TNXP
Industry

Key metrics

Basic
Market capitalization
$210.4m
Enterprise Value
$85.1m
Net debt
positive
Cash
$125.3m
Shares outstanding
7.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
21.4 | 18.2
EV/Sales
8.7 | 7.3
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
85.7%
Return on Equity
-93.2%
ROCE
-50.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.8m | $11.6m
EBITDA
$-82.5m | -
EBIT
$-84.5m | $-108.2m
Net Income
$-81.4m | $-100.3m
Free Cash Flow
$-65.4m
Growth (TTM | estimate)
Revenue
-21.1% | 14.8%
EBITDA
8.6% | -
EBIT
11.3% | -39.2%
Net Income
45.4% | 22.9%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
29.3%
EBITDA
-839.1% | -
EBIT
-859.3%
Net
-828.2% | -865.3%
Free Cash Flow
-665.1%
More
EPS
$-11.1
FCF per Share
$-8.7
Short interest
15.2%
Employees
81
Rev per Employee
$120.0k
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
88%
Hold
13%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9.83 9.83
21% 21%
100%
- Direct Costs 6.95 6.95
29% 29%
71%
2.88 2.88
7% 7%
29%
- Selling and Administrative Expenses 50 50
34% 34%
505%
- Research and Development Expense 36 36
41% 41%
363%
-82 -82
9% 9%
-839%
- Depreciation and Amortization 1.98 1.98
60% 60%
20%
EBIT (Operating Income) EBIT -84 -84
11% 11%
-859%
Net Profit -81 -81
45% 45%
-828%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Positive
Proactive Investors
4 days ago
Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025.   The biotechnology company said Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix.
Neutral
GlobeNewsWire
4 days ago
Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N...
Neutral
GlobeNewsWire
5 days ago
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today